Open AccessSodium glucose co-transporter 2 inhibition reduces succinate levels in diabetic mice
Author(s) -
Lakshini Y. Herat,
Natalie C. Ward,
Aaron L. Magno,
Elizabeth Rakoczy,
Márcio Galindo Kiuchi,
Markus P. Schlaich,
Vance B. Matthews
Publication year - 2020
Publication title -
world journal of gastroenterology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v26.i23.3225
Subject(s) - medicine , endocrinology , diabetes mellitus , dapagliflozin , renal glucose reabsorption , type 2 diabetes , insulin , diabetic retinopathy , kidney , chemistry
Type 1 diabetes (T1D) is associated with major chronic microvascular complications which contribute significantly to diabetes associated morbidity. The protein primarily responsible for glucose reabsorption in the kidney is sodium glucose co-transporter 2 (SGLT2). Presently, SGLT2 inhibitors are widely used in diabetic patients to improve blood glucose levels and prevent cardiovascular and renal complications. Given the broad therapeutic application of SGLT2 inhibitors, we hypothesised that SGLT2 inhibition may exert its protective effects via alterations of the gut microbiome and tested this in a type 1 diabetic mouse model of diabetic retinopathy.